Corbus Pharmaceuticals Appoints Chief Business Officer, Details Equity Compensation and Upcoming Clinical Data
CRBP sits 49% above its 52-week low of $6.72.
Summary
Corbus Pharmaceuticals appointed a new Chief Business Officer with significant M&A experience and announced upcoming clinical data presentations for its lead oncology asset, CRB-701, at ASCO.
Key Events · Executive and Board Changes · CRBP
-
Strategic Chief Business Officer Appointment
Nishant Saxena, a former Evercore Managing Director with deep expertise in M&A, licensing, and capital markets, was appointed as Chief Business Officer, a critical role as the company transitions to registrational-stage clinical development.
-
Substantial Equity Compensation for CBO
Mr. Saxena received 192,300 stock options and 58,300 restricted stock units, valued at approximately $2.5 million at the current stock price, reflecting a significant incentive package.
-
Upcoming Clinical Data Presentations
The company will host a conference call on May 26, 2026, to discuss updated Phase 1/2 clinical data for CRB-701, with further presentations scheduled for the 2026 ASCO Annual Meeting on May 29 and May 30.
-
Pipeline Milestones Highlighted
Corbus reiterated anticipated milestones, including the initiation of a registrational study for CRB-701 and the completion of the CANYON-1 Phase 1b study for CRB-913.
Analysis · CRBP · Life Sciences
Corbus Pharmaceuticals has appointed Nishant Saxena, a former Evercore Managing Director with extensive M&A and capital markets experience, as its first Chief Business Officer. This strategic hire is crucial as the company advances its pipeline towards registrational-stage development. The filing also details upcoming presentations of CRB-701 clinical data at ASCO and provides updates on key pipeline milestones, reinforcing the company's progress in oncology and obesity.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRBP was trading at $10.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $180.3M. The 52-week trading range was $6.72 to $20.56. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.